Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: AHF Challenges Gilead over AIDS Drug Price Gouging of U.S. Gov't Programs on Stribild




 

Rock Hill Herald Online (Rock Hill, S.C.) (01.29.13) Aids Weekly Plus

The AIDS Healthcare Foundation (AHF) reported that Gilead Sciences, Inc. charges US HIV patients $28,500 per year for the new HIV drug Stribild, in comparison to $16,600 per patient per year in Canada and European countries with price controls. AHF president Michael Weinstein questioned why Gilead was willing to charge US government programs like ADAP and US HIV patients 42 percent more per patient, per year than price-controlled countries with stronger economies. When the FDA approved Stribild, a drug that combines four HIV medicines in one pill, in September 2012, Gilead immediately set the U.S. Wholesale Acquisition Cost (WAC) at $28,500. Stribild costs 35 percent more per patient, per year than Atripla, Gilead’s best selling three-in-one combination drug. The WAC for other Gilead drugs also went up in 2013: Atripla increased 6 percent to $1,878.23 per month; Complera went up 5.8 percent to $1,936.53; Emtriva rose by 5.5 percent to $478.45; and Viread increased 6 percent to $771.39. Weinstein stated AHF challenged Gilead’s pricing strategy to educate people in the United States about the cost of HIV medicines and to pressure Gilead into changing its US pricing policies.



 


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in February 1, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.